Literature DB >> 29577605

Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis.

T Sinegre1,2, C Duron3,4, T Lecompte5,6, B Pereira7, S Massoulier3, G Lamblin3, A Abergel3,4, A Lebreton1,2.   

Abstract

Essentials The role of increased factor VIII in cirrhosis-induced hypercoagulability has never been demonstrated. Factor VIII and protein C effects were characterized by thrombin generation with thrombomodulin. Factor VIII elevation plays a significant role in cirrhosis-induced plasma hypercoagulability. Only protein C and factor VIII normalization led to thrombin generation similar to controls.
SUMMARY: Background In cirrhosis, thrombin generation (TG) studied in the presence of thrombomodulin (TM) indicates plasma hypercoagulability. Although the role of protein C (PC) deficiency has been investigated, the influence of an increase in the factor VIII level has never been addressed. Objectives We investigated the roles of high FVIII and low PC levels in increased TG in the presence of TM. Methods Blood samples were prospectively collected from 35 healthy controls and 93 patients with cirrhosis (Child-Turcotte-Pugh [CTP]-A, n = 61; CTP-B, n = 19; and CTP-C, n = 13) and FVIII levels > 150% (n = 48) and/or PC levels < 70% (n = 88). TG was performed with tissue factor (5 pm), phospholipids, and TM (4 nm). FVIII and PC levels were normalized by adding an inhibitory anti-FVIII antibody and exogenous PC, respectively. Results The endogenous thrombin potential (ETP) in the presence of TM was higher in patients than in controls. After FVIII normalization, the ETP (median) decreased from 929 nm min to 621 nm min (CTP-A), 1122 nm min to 1082 nm min (CTP-B), and 1221 nm min to 1143 nm min (CTP-C); after PC normalization, it decreased from 776 nm min to 566 nm min (CTP-A), 1120 nm min to 790 nm min (CTP-B), and 995 nm min to 790 nm min (CTP-C). The ETP was reduced by 17% and 30%, respectively, but normal TG was not restored. When both FVIII and PC levels were normalized, the ETP decreased from 929 nm min to 340 nm min (CTP-A), 1122 nm min to 506 nm min (CTP-B), and 1226 nm min to 586 nm min (CTP-C), becoming similar to control levels. Conclusion Cirrhosis-induced plasma hypercoagulability, as demonstrated in these experimental conditions, can be partly explained by opposite changes in two factors: PC level (decrease) and FVIII level (increase).
© 2018 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  cirrhosis; factor VIII; hypercoagulability; protein C; thrombin generation

Mesh:

Substances:

Year:  2018        PMID: 29577605     DOI: 10.1111/jth.14011

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  11 in total

Review 1.  Portal Vein Thrombosis In Cirrhosis: Interventional Treatment Options.

Authors:  Christopher Molvar; Parag Amin
Journal:  Curr Gastroenterol Rep       Date:  2021-10-15

2.  Blood products and liver transplantation: A strategy to balance optimal preparation with effective blood stewardship.

Authors:  Christopher J Little; Glen E Leverson; Laura L Hammel; Joseph P Connor; David P Al-Adra
Journal:  Transfusion       Date:  2022-08-20       Impact factor: 3.337

Review 3.  Targeting von Willebrand factor in liver diseases: A novel therapeutic strategy?

Authors:  Dafna J Groeneveld; Lauren G Poole; James P Luyendyk
Journal:  J Thromb Haemost       Date:  2021-05-03       Impact factor: 16.036

4.  The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease.

Authors:  Bernhard Scheiner; Patrick G Northup; Anselm B Gruber; Georg Semmler; Gerda Leitner; Peter Quehenberger; Johannes Thaler; Cihan Ay; Michael Trauner; Thomas Reiberger; Ton Lisman; Mattias Mandorfer
Journal:  Liver Int       Date:  2020-03-04       Impact factor: 5.828

5.  Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay.

Authors:  Jun Wan; Lara N Roberts; Wasiliki Hendrix; Joke Konings; Tsai-Wing Ow; Liane Rabinowich; Omar Barbouti; Bas de Laat; Roopen Arya; Vishal C Patel; Mark Roest; Ton Lisman; William Bernal
Journal:  J Thromb Haemost       Date:  2020-02-18       Impact factor: 5.824

6.  Clinical factors associated with massive pulmonary embolism and PE-related adverse clinical events.

Authors:  Praveen Hariharan; Nicholas Giordano; Alona Muzikansky; Christopher Kabrhel
Journal:  Int J Cardiol       Date:  2021-01-31       Impact factor: 4.164

7.  Thrombin Generation in Chronic Liver Diseases-A Pilot Study.

Authors:  Liliana Vecerzan; Ariela Olteanu; Ionela Maniu; Adrian Boicean; Călin Remus Cipăian; Horaţiu Dura; Sorin Radu Fleacă; Romeo Gabriel Mihăilă
Journal:  Healthcare (Basel)       Date:  2021-05-08

Review 8.  Step by Step: Managing the Complications of Cirrhosis.

Authors:  Irene C Perez; Fabian J Bolte; William Bigelow; Zachary Dickson; Neeral L Shah
Journal:  Hepat Med       Date:  2021-05-25

9.  Association of ABO Blood Type with Bleeding Severity in Patients with Acute Gastroesophageal Variceal Bleeding.

Authors:  Wei-Yu Lin; Ming-Yuan Hong; Chih-Hao Lin; Peng-Peng Chang; Shao-Chung Chu; Chia-Lung Kao
Journal:  Medicina (Kaunas)       Date:  2021-12-03       Impact factor: 2.430

10.  Properties of Plasma Clots in Adult Patients Following Fontan Procedure: Relation to Clot Permeability and Lysis Time-Multicenter Study.

Authors:  Maciej Skubera; Aleksandra Gołąb; Dariusz Plicner; Joanna Natorska; Michał Ząbczyk; Olga Trojnarska; Anna Mazurek-Kula; Monika Smaś-Suska; Agnieszka Bartczak-Rutkowska; Piotr Podolec; Lidia Tomkiewicz-Pająk
Journal:  J Clin Med       Date:  2021-12-20       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.